Your browser doesn't support javascript.
loading
Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.
Fleming, Steven T; Hamilton, Ann S; Sabatino, Susan A; Kimmick, Gretchen G; Wu, Xiao-Cheng; Owen, Jean B; Huang, Bin; Hwang, Wenke.
Afiliação
  • Fleming ST; *Department of Epidemiology, University of Kentucky College of Public Health, Lexington, KY †Keck School of Medicine of University of Southern California, Los Angeles, CA ‡Centers for Disease Control and Prevention, Atlanta, GA §Duke University Medical Center, Durham, NC ∥Louisiana State University Health Sciences Center, New Orleans, LA ¶American College of Radiology Clinical Research Center, Philadelphia, PA #University of Kentucky Markey Cancer Center, Lexington, KY **Pennsylvania State Unive
Med Care ; 52(9): e58-64, 2014 Sep.
Article em En | MEDLINE | ID: mdl-23222532
ABSTRACT

BACKGROUND:

As evidence-based guidelines increasingly define standards of care, the accurate reporting of patterns of treatment becomes critical to determine if appropriate care has been provided. We explore the level of agreement between claims and record abstraction for treatment regimens for prostate cancer.

METHODS:

Medicare claims data were linked to medical records abstraction using data from the Centers for Disease Control and Prevention's National Program of Cancer Registry-funded Breast and Prostate Patterns of Care study. The first course of therapy included surgery, radiation therapy (RT), and hormonal therapy with luteinizing hormone-releasing hormone agonists.

RESULTS:

The linked sample included 2765 men most (84.7%) of whom had stage II prostate cancer. Agreement was excellent for surgery (κ=0.92) and RT (κ=0.92) and lower for hormonal therapy (κ=0.71); however, most of the discrepancies were due to greater number of patients reported who received hormonal therapy in the claims database than in the medical records database. For some standard multicomponent management strategies sensitivities were high, for example, hormonal therapy with either combination RT (86.9%) or cryosurgery (96.6%).

CONCLUSIONS:

Medicare claims are sensitive for determining patterns of multicomponent care for prostate cancer and for detecting use of hormonal therapy when not reported in the medical records abstracts.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Revisão da Utilização de Seguros / Prontuários Médicos / Coleta de Dados / Medicare Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Revisão da Utilização de Seguros / Prontuários Médicos / Coleta de Dados / Medicare Idioma: En Ano de publicação: 2014 Tipo de documento: Article